CN106749008A - A kind of method of micronization of maleic acid QAB-149 and its application - Google Patents
A kind of method of micronization of maleic acid QAB-149 and its application Download PDFInfo
- Publication number
- CN106749008A CN106749008A CN201510813416.XA CN201510813416A CN106749008A CN 106749008 A CN106749008 A CN 106749008A CN 201510813416 A CN201510813416 A CN 201510813416A CN 106749008 A CN106749008 A CN 106749008A
- Authority
- CN
- China
- Prior art keywords
- maleic acid
- qab
- aqueous suspensions
- acid qab
- micronizing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
- C07D215/26—Alcohols; Ethers thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B02—CRUSHING, PULVERISING, OR DISINTEGRATING; PREPARATORY TREATMENT OF GRAIN FOR MILLING
- B02C—CRUSHING, PULVERISING, OR DISINTEGRATING IN GENERAL; MILLING GRAIN
- B02C17/00—Disintegrating by tumbling mills, i.e. mills having a container charged with the material to be disintegrated with or without special disintegrating members such as pebbles or balls
- B02C17/10—Disintegrating by tumbling mills, i.e. mills having a container charged with the material to be disintegrated with or without special disintegrating members such as pebbles or balls with one or a few disintegrating members arranged in the container
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B02—CRUSHING, PULVERISING, OR DISINTEGRATING; PREPARATORY TREATMENT OF GRAIN FOR MILLING
- B02C—CRUSHING, PULVERISING, OR DISINTEGRATING IN GENERAL; MILLING GRAIN
- B02C17/00—Disintegrating by tumbling mills, i.e. mills having a container charged with the material to be disintegrated with or without special disintegrating members such as pebbles or balls
- B02C17/18—Details
- B02C17/20—Disintegrating members
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Pulmonology (AREA)
- Medicinal Chemistry (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides a kind of method of maleic acid QAB-149 micronizing, it is characterised in that methods described includes：1) maleic acid QAB-149 is dispersed in water, obtains uniform maleic acid QAB-149 aqueous suspensions；2) to step 1) the maleic acid QAB-149 aqueous suspensions that obtain are micronized, and make the particle diameter of maleic acid QAB-149 in aqueous suspensions in 0.5~5 μ m, the aqueous suspensions of the maleic acid QAB-149 being micronized；Preferably, it is micronized using stirring-type bead mill method；3) by step 2) aqueous suspensions of the maleic acid QAB-149 of micronizing that obtain carry out freeze-drying, obtain the powder of appropriate particle size scope.The method of the present invention limited can avoid medicine from being thermally decomposed, and the medicine rate of recovery is high, and environmental pollution is small.
Description
Technical field
The invention belongs to biomedicine field.Specifically, the present invention relates to a kind of maleic acid indenes up to spy
The method of micronization of sieve.
Background technology
Adult chronic's obstructive disease of lung (COPD) is a kind of important chronic respiratory disease, is suffered from
Patient's number is more, and case fatality rate is high, social economical burden weight, it has also become an important public health problem.
Because it slowly carries out sexual development, the labour capacity and quality of life of patient are had a strong impact on.COPD is current
The 4th of the global cause of death is occupied, the World Bank/World Health Organization announces, to the year two thousand twenty COPD
The 5th of world's disease financial burden will be occupied.In China, COPD is equally serious harm people's body
The important chronic respiratory disease of body health.7 Adult Groups of area 20,245 of China are carried out in the recent period
Investigation, COPD illness rates are accounted for more than 40 years old the 8.2% of crowd, and the height of its illness rate is very surprising.COPD
Patient is after acute attack stage, though clinical symptoms have been alleviated, its PFT still deteriorates in continuation,
And the influence of the reduction and extraneous various adverse factors due to self-defense and immunologic function, it is often anti-
Recurrence is made, and gradually produces various Cardiopulmonary Complications.
QAB-149 is bronchodilators, belongs to long-acting suction β2Receptor stimulating agent (LABA) class, fits
For the maintaining treatment of Adult chronic's obstructive disease of lung (COPD) patient.QAB-149 has 5 points
The characteristics of clock works, continues 24 hours.The structural formula of maleic acid QAB-149 is as follows：
QAB-149 is produced by Novartis Co., Ltd of Switzerland, on more than 70, whole world country and ground since 2009
Area lists, wherein maleic acid QAB-149 powder spray 2009 Europe listing (specification be 150 μ g and
300μg)；2011 in U.S.'s listing (specification is 75 μ g), trade name Arcapta；The same year exists
Japan's listing (specification is 150 μ g)；In June, 2012 is ratified in China's listing (specification through national Bureau of Drugs Supervision
It is 150 μ g), trade nameIt is domestic first granted for treating COPD
LABA class unitary agents.Clinical test results show：QAB-149 takes once a day can make branch
Tracheae diastole reaches more than 24h, and compared with salmeterol (LABA classes early stage medicine), it can significantly change
In kind, the Major Clinical evaluation index of patients of severe COPD, while security and tolerance are good；With
C19H22BrNO4S2 (LAMA classes medicine) is compared, QAB-149 therapeutic equivalence in terms of Pulmonary Function improvement,
Tiotropium Bromide is significantly better than in terms of expiratory dyspnea and quality of making the life better is alleviated.
Dry powder inhaler formulations have strict demand to active component average grain diameter.According to respiratory tract physiology structure,
To make the medicine sucked through respiratory tract effectively be distributed or being deposited on therapentic part, the granularity of medicine is strict
Control, generally below 7 μm, granularity excessive (being more than 10 μm) or too small (being less than 0.5 μm) can
Can prevent medicine from effectively depositing, curative effect reduction.For induction type powder spray, first have to carry out medicine
Micronization processes.At present, active component can be by air-flow crushing, speed lapping, ball mill or spray
One or more breaking methods in mist (freezing) drying etc. are combined.
The Chinese patent application of the A of Application No. CN 102858320 discloses one kind and prepares respirable dry powder
The method of the carrier granular of preparation, the method uses air-flow crushing, and excipient and additive are carried out into common powder
It is broken.
The Chinese patent application of the A of Application No. CN 103347501 discloses a kind of dry powder formulations that prepare
Method.The method is micronized using spray drying process to bulk drug, prepare for treat it is obstructive or
The particle comprising two or various active composition of inflammatory respiratory disease.
Once turning into micro mist, its specific surface area can increase medicine, and Electronic Structure and crystal structure also can
Skin effect, small-size effect corresponding that significant changes occur, that produce block or meal medicine not have
And quantum effect, while the adsorptivity of drug powder, surface charge and surface adhesion force can also occur significantly
Change.
It is many in prior art as described in above-mentioned patent application indenes is reached using air-flow crushing and spray drying process
Special sieve active compound carries out micronization processes.QAB-149 pharmacological action is strong, and only 75 μ g can produce pharmacology to make
With.When being micronized using air-flow crushing and spray drying process, amount of heat can be produced, may led
The crystal transfer of medicine is caused, influence will also result on the stability of medicine.Meanwhile, the medicine powder after crushing
The last great enhancing of adsorptivity, can largely stick to vessel surface, cause the reduction of medicine yield.Above two
Method of micronization, without effective retracting device, the drug powder after crushing suspends in atmosphere,
Environmental pollution can be caused, the healthy of operator is caused harm.
The content of the invention
The formulation characteristic of physicochemical property and powder spray in view of QAB-149, in order to overcome prior art
Deficiency, combine wet grinding and freeze drying process to maleic acid QAB-149 the invention provides one kind
The method being micronized.For powder spray, the particle size and smooth in appearance degree of medicine,
The separating power of medicine and lactose is directly affected, and then influences medicine in the effective precipitation of lung.Cause
This, it is necessary to assure medicine is during crushing, and its surface smooth degree is unaffected, and after crushing
Diameter of aspirin particle need in appropriate particle size range and be evenly distributed.Just research finds the present invention, with it
He compares method of micronization, and not only grinding efficiency is high for wet grinding, and in process of lapping, does not destroy
The outer smooth degree of drug particle, particle complete appearance after crushing, and granule size is controllable.And it is cold
Lyophilized drying process can effectively remove the residual moisture in medicine, and the drug powder quality after freezing is dredged
Pine, good dispersion more conducively in use, realizes efficiently separating for medicine and lactose.Therefore,
This research carries out micronization processes using wet grinding and freeze drying process to medicine, can meet dust cloud
Agent to the processing requirement of bulk drug, relative to other method of micronization.
A kind of method of maleic acid QAB-149 micronizing, it is characterised in that methods described includes：
1) maleic acid QAB-149 is dispersed in water, obtains uniform maleic acid QAB-149 water and hang
Liquid；
2) to step 1) the maleic acid QAB-149 aqueous suspensions that obtain are micronized, in making aqueous suspensions
In 0.5~5 μ m, the maleic acid indenes being micronized reaches spy to the particle diameter of maleic acid QAB-149
The aqueous suspensions of sieve；Preferably, it is micronized using stirring-type bead mill method；
3) by step 2) aqueous suspensions of the maleic acid QAB-149 of micronizing that obtain carry out freeze-drying,
Obtain the powder of appropriate particle size scope.
Preferably, step 1) described in maleic acid QAB-149 in maleic acid QAB-149 aqueous suspensions
Concentration is 1g~50g/L；Preferably 5~20g/L.
Preferably, step 1) in be by stirring and/or ultrasonically treated make the maleic acid QAB-149
It is finely dispersed in water；Preferably, 5~10min is processed with the power ultrasonic of 60~100HZ.
Preferably, step 2) described in the D of the grinding bead of ball mill that is used of stirring-type bead mill method50
It is 0.6mm to be worth, and the rotating speed of the ball mill is 1000~3000rpm；Preferably, the ball mill
Rotating speed be 1500~2000rpm, cycle period be 1~3 time.
In an embodiment of the invention, step 3) described in freeze-drying be by bag
Include the method realization of following step：
A) by step 2) aqueous suspensions of the maleic acid QAB-149 of micronizing that obtain are inserted in cold hydrazine,
With -40~-30 DEG C of temperature pre-freeze；
B) lyophilization 20~40 hours；
C) parsing-desiccation 2~6 hours, that is, obtain the maleic acid QAB-149 of dry micronizing.
In an embodiment of the invention, in the step a), the horse of the micronizing
The liquid height for carrying out the aqueous suspensions of sour QAB-149 is the maleic acid QAB-149 for holding the micronizing
Aqueous suspensions container height 1/4~1/3.
In an embodiment of the invention, the lyophilization is carried out according to following procedure
's：
Processed 240 minutes at -30 DEG C first, then processed 200 minutes with -25 DEG C, followed by with -10
DEG C treatment 120 minutes, finally with -5 DEG C treatment 240 minutes complete lyophilization.
In an embodiment of the invention, the parsing-desiccation is carried out according to following procedure
's：
Processed 360 minutes at 0 DEG C first, then processed 300 minutes at 10 DEG C, followed by 15
DEG C treatment 240 minutes, end temperature be down to -121 DEG C completion parsing-desiccations.
Maleic acid indenes invention further provides the micronizing prepared according to above-mentioned method reaches spy
Application of sieve in powder spray is prepared.Preferably, also include in the powder spray pharmaceutically acceptable
Auxiliary material.
The present invention is using wet grinding to QAB-149 bulk drug micronization processes.First medicinal powder is dispersed in suitable
In suitable solvent, the suspension that will be obtained carries out wet-milling in the presence of medium of milling.Started in equipment
Cheng Zhong, is rotated using the high speed of rotating shaft, drives the rotation of medium of milling, drug particles and medium of milling
Interaction produce enough energy that medicine crystal is changed into micro mist.Due to the method, in micro mist
During change, medicine is dispersed in solvent all the time, the less residue inside container, therefore, medicine
The rate of recovery is high, and environmental pollution is small.
The present invention further employs the QAB-149 medicine that freeze-drying is micronized.Freeze-drying
It is, by the medicine containing large quantity of moisture, cooling to be carried out in advance and is frozen into solid, then in low-temp low-pressure bar
Under part, make vapor directly distil out from solid, and the steam of solidifying distillation caught with condensation method,
So that the dry method of medicine dehydration.Freeze-drying limited can avoid medicine from being thermally decomposed, meanwhile,
Environmental pollution is small.
In sum, the present invention is micronized using stirring-type ball mill (wet grinding) to bulk drug,
And treatment is dried to suspension using freeze-drying, obtain dry medication powder.
Brief description of the drawings
Hereinafter, embodiment of the present invention is described in detail with reference to accompanying drawing, wherein：
After Fig. 1 a~Fig. 1 c are respectively the micronizing of embodiment 1~3, the size distribution of medicine in suspension；
Wherein, the particle diameter distribution of medicine after the micronizing obtained when Fig. 1 a are 500~1000rpm of rotating speed；Figure
The particle diameter distribution of medicine after the micronizing that 1b is obtained when being 1500~2000rpm of rotating speed；Fig. 1 c are to turn
The particle diameter distribution of medicine after the micronizing that 1500~2000rpm of speed is obtained.
Fig. 2 is the size distribution of medicine in suspension after embodiment 4 is micronized.
Fig. 3 is microphotograph (1200 times) before the micronizing of maleic acid QAB-149 bulk drug.Ratio
100 μm of chi.
Fig. 4 is medicine microphotograph (5000 times) after the micronizing of maleic acid QAB-149.Engineer's scale
20μm。
Specific embodiment
With reference to embodiments the present invention is further illustrated with accompanying drawing.It should be appreciated that following embodiments are only
It is to be further elucidated to of the invention, rather than limitation of the present invention.
During wet-milling, after the selection of grinding bead diameter is, it is necessary to consider grinding efficiency and grinding
The size of drug particle.Inventor has found that under the conditions of same rotational speed, the diameter of grinding bead is smaller,
In process of lapping, the resistance of generation is bigger, and single milling time is more long, often once grinds i.e. reachable
To target grain size, but medicine particle size heterogeneity generally in system, increasing cycle-index, can make again
Drug particle particle diameter reduces rapidly, while reducing the stability of medicine there may be substantial amounts of heat again.
In contrast, the big grinding bead of particle diameter, during grinding produce resistance it is small, single milling time it is short, it is necessary to
Repeatedly grinding can be only achieved preferable particle size range.Inventor has considered grinding effect after research
Rate, number of times and particle size, the diameter D of grinding bead is determined eventually through experimental verification50For
0.6mm, the selection to grinding power, cycle-index and drug concentration is illustrated with embodiment.
Freeze drying process generallys include pre-freeze, lyophilization and the part of parsing-desiccation three.Wherein, in advance
Jelly refers to that lyophilized material will be needed to be placed in cold hydrazine in advance, is cooled to -40 DEG C~-30 DEG C or so, is treated
Product fully charge, you can distilled.
The lyophilization (also known as primary drying) of product is carried out under high vacuum, required for distillation
Latent heat the surface of dried material is sent to by ambient heat process by thermal source, then again in
What portion's diabatic process was sent to the distillation of ice in material actually occurs place.Produced vapor is by inside
Mass transport process reaches the surface of material, then is transferred to steam trap (cold-trap) by External mass transfer process
In.During pressure reduction, it is necessary to the freezing state of article in case is kept, with anti-spilled container.
When whole ice crystals are removed, lyophilization is just completed, and can now remove the moisture of material 90% or so.
It is that water is removed in the form of ice crystal that first stage dries, therefore freezes temperature and the distillation of layer
The pressure at interface must all control below, just not causing ice crystal molten in product plait point (or disintegration temperature)
Change.But for absorption water, its absorption energy is high, if not providing enough energy, water is impossible to
Parsed in adsorbed state, it is therefore desirable to parsing-desiccation (also known as redrying) is carried out, to remove
After going remaining adsorption moisture in material, second stage to dry, the content of product residual moisture typically may be used
To control between 0.5%-4%, by material moisture after parsing-desiccation compared with simple lyophilization,
Significantly reduce.
Embodiment 1Rotating speed is preferred in micromill process
(1) drug micronization：0.5g maleic acids QAB-149 is taken as in beaker, 100mL is added
Purified water, is stirred with glass bar, and ultrasound is to dispersed.Using stirring-type ball mill to medicine
Be micronized, rotating speed be respectively 500~1000rpm, 1500~2000rpm and 2500~
3000rpm, the diameter D50 of grinding bead is 0.6mm, is circulated 2 times.Using Malvern laser particle size
Instrument determines size distribution, as a result as shown in Fig. 1 a~Fig. 1 c, is respectively adopted under three kinds of rotating speeds, after grinding
Diameter of aspirin particle D50 be respectively 0.879 μm, 1.892 μm, 1.988 μm.
(2) for powder spray, the diameter of aspirin particle needs after micronizing are appropriately sized and uniform, when
When diameter of aspirin particle is in 0.5 μm~5 μ ms, lung can be effectively deposited on, from Fig. 1 a~Fig. 1 c
As can be seen that when rotating speed is 1500~2000rpm and 2500~3000rpm, medicine grain after grinding
Son is uniform in size, but inventor is had found in process of lapping, with the raising of rotating speed, in process of lapping
The resistance of middle generation is bigger, and heat production is more, makes the stability of medicine and reduces, while carrying with rotating speed
Height, solution can produce substantial amounts of foam, medicine to swim in foam surface, be unfavorable for that next step freezes work
The carrying out of skill, therefore, summary experimental result determines that rotating speed is 1500~2000rpm.
Embodiment 2Cycle-index is preferred in micro mist technique
(1) drug micronization：0.5g maleic acids QAB-149 is taken as in beaker, 100mL is added
Purified water, is stirred with glass bar, and ultrasound is to dispersed.Using stirring-type ball mill to medicine
It is micronized, rotating speed is 2000rpm, the diameter D of grinding bead50It is 0.6mm, circulation is respectively
1st, 2,3 times.
The influence that the cycle-index of table 1 is distributed to drug particle size
Wherein, D10、D50And D90The cumulative particle sizes percentile of respectively one sample reaches
10%th, 50% and 90% when corresponding particle diameter, be the common counter for evaluating diameter of aspirin particle distribution.
(2) under the conditions of fixed rotating speed, with the increase of grinding number of times, the particle diameter of main ingredient in suspension
Taper into and uniformly, but with the increase of cycle-index, the change is not obvious, and have big in suspension
Amount foam is produced, and the heat produced during grinding, can also influence the stability of medicine, therefore, circulation
Number of times is defined as 1~3 time.
Embodiment 3The ratio of medicine and solvent is preferred in micro mist technique
A diameter of 0.6mm of fixed grinding bead, rotating speed is 2000rpm, and cycle-index is 2 times, by
It is 100ml in the loading amount of equipment cavity, therefore quantity of solvent is fixed as 100ml.Medicine is investigated with solvent
Ratio is 1g：100ml；50g：100ml and 100g：The dispersity of medicine during 100ml.
Inventor find, because maleic acid QAB-149 has certain hydrophobicity, disperse in water compared with
Be difficulty, it is impossible to disperse complete medicine then can agglomerate, be suspended in solvent surface, even if circulation is multiple,
Expected size distribution can not be reached；And if main ingredient ratio is too low in system, grinding can be influenceed again
Efficiency, is unfavorable for industrialized production, therefore, summary situation, this experiment determine medicine with it is molten
The ratio of agent is 1~50g：100ml.
Implement4 lyophilized techniques of example-lyophilization
(1) drug micronization：1g maleic acids QAB-149 is taken as in beaker, 100mL is added
Purified water, is stirred with glass bar, and ultrasound is to dispersed.Using stirring-type ball mill to medicine
It is micronized, power is 1500rpm, is circulated 2 times.Grain is determined using Malvern laser particle analyzer
Degree distribution, as a result as shown in Fig. 2 the particle diameter distribution of medicine is D after micronizing50It is 1.189 μm,
PDI is 0.272, illustrates that the diameter of aspirin particle after crushing is small and uniform, is met in powder spray to bulk drug
The requirement of particle diameter.
(2) freeze-drying：
a：The pre-freeze of sample：Sample is put into cold hydrazine, cold hydrazine temperature is reduced to -40 DEG C.
b：After sample freezes reality, the lyophilized program of setting is as follows：
c：System is vacuumized
d：Operation program
(3) dried powder after freezing is taken out, sealing preserve determines the moisture of lyophilized rear bulk drug
It is 12.3%.For powder spray, too high moisture not only influences lactose to be separated with medicine, and
And it is unfavorable for the long-term preservation of medicine, therefore, it is simple bulk drug to be entered using lyophilization technique
Row efficient drying.
Embodiment 5Lyophilized technique-lyophilization and parsing-desiccation
(1) drug micronization：1g maleic acids QAB-149 is taken as in beaker, 100mL is added
Purified water, is stirred with glass bar, and ultrasound is to dispersed.Using stirring-type ball mill to medicine
It is micronized, power is 1500rpm, is circulated 2 times.
(2) freeze-drying：
a：The pre-freeze of sample：Sample is put into cold hydrazine, cold hydrazine temperature is reduced to -37.5 DEG C.
b：After sample freezes reality, the lyophilized program of setting is as follows：
Wherein, program 1~4 is the lyophilization stage, and program 5~8 is the parsing-desiccation stage.
c：System is vacuumized
d：Operation program
(3) dried powder after freezing, sealing preserve are taken out, and determines the moisture of bulk drug
It is 6.1%.Compared with simple lyophilization, the technique being combined using lyophilization and parsing-desiccation,
The water content of medicine can preferably be reduced.
Embodiment 6The preparation of maleic acid QAB-149 micro mist
(1) drug micronization：1.5g maleic acids QAB-149 is taken as in beaker, 80mL is added
Purified water, is stirred with glass bar, and ultrasound is to dispersed.Using stirring-type ball mill to medicine
It is micronized, power is 2000rpm, is circulated 3 times.After sample all pours into grinder, use
Remaining 20mL purified waters rinse charge door, will remain drug irrigation in a device out, collect
Whole effluxes, mixing.
(2) freeze-drying：
a：The pre-freeze of sample：Sample is put into cold hydrazine, cold hydrazine temperature is reduced to -37.5 DEG C.
b：After sample freezes reality, the lyophilized program of setting is as follows：
c：System is vacuumized
d：Operation program
(3) dried powder after freezing, sealing preserve are taken out.After bulk drug and micronization processes
Drug powder observed under ESEM, as shown in Figure 3,4, outside the medicine after micronization processes
See completely, particle diameter is small and uniform.
Although present invention has been a certain degree of description, it will be apparent that, do not departing from spirit of the invention
Under conditions of scope, the appropriate change of each condition can be carried out.It is appreciated that the invention is not restricted to institute
State embodiment, and be attributed to the scope of claim, its equivalent for including each factor.
Claims (10)
1. a kind of method that maleic acid QAB-149 is micronized, it is characterised in that methods described includes：
1) maleic acid QAB-149 is dispersed in water, obtains uniform maleic acid QAB-149 water and hang
Liquid；
2) to step 1) the maleic acid QAB-149 aqueous suspensions that obtain are micronized, in making aqueous suspensions
In 0.5~5 μ m, the maleic acid indenes being micronized reaches spy to the particle diameter of maleic acid QAB-149
The aqueous suspensions of sieve；Preferably, it is micronized using stirring-type bead mill method；
3) by step 2) aqueous suspensions of the maleic acid QAB-149 of micronizing that obtain carry out freeze-drying,
Obtain the powder of appropriate particle size scope.
2. the method for claim 1, it is characterised in that step 1) described in maleic acid indenes
The concentration of maleic acid QAB-149 is 1g~50g/L in Da Teluo aqueous suspensions；Preferably 5~20g/L.
3. method as claimed in claim 1 or 2, it is characterised in that step 1) in be by stirring
Mix and/or ultrasonically treated make the maleic acid QAB-149 finely dispersed in water；Preferably, with
The power ultrasonic of 60~100HZ processes 5~10min.
4. the method as any one of claims 1 to 3, it is characterised in that step 2) in institute
State the D of the grinding bead of the ball mill that stirring-type bead mill method is used50It is 0.6mm to be worth, the ball mill
Rotating speed be 1000~3000rpm；Preferably, the rotating speed of the ball mill is 1500~2000rpm,
Cycle period is 1~3 time.
5. the method as any one of Claims 1 to 4, it is characterised in that step 3) it is described
Freeze-drying be to be realized by the method that comprises the steps：
A) by step 2) aqueous suspensions of the maleic acid QAB-149 of micronizing that obtain are inserted in cold hydrazine,
With -40~-30 DEG C of temperature pre-freeze；
B) lyophilization 20~40 hours；
C) parsing-desiccation 2~6 hours, that is, obtain the maleic acid QAB-149 of dry micronizing.
6. method as claimed in claim 5, it is characterised in that described micro- in the step a)
The liquid height of the aqueous suspensions of the maleic acid QAB-149 of efflorescence is the maleic acid for holding the micronizing
The 1/4~1/3 of the container height of the aqueous suspensions of QAB-149.
7. method as claimed in claim 5, it is characterised in that the lyophilization is according to following
What program was carried out：
Processed 240 minutes at -30 DEG C first, then processed 200 minutes with -25 DEG C, followed by with -10
DEG C treatment 120 minutes, finally with -5 DEG C treatment 240 minutes complete lyophilization.
8. method as claimed in claim 5, it is characterised in that the parsing-desiccation is according to following
What program was carried out：
Processed 360 minutes at 0 DEG C first, then processed 300 minutes at 10 DEG C, followed by 15
DEG C treatment 240 minutes, end temperature be down to -121 DEG C completion parsing-desiccations.
9. the maleic acid indenes of micronizing prepared by the method as any one of claim 1~8 reaches
Application of special sieve in powder spray is prepared.
10. application as claimed in claim 9, it is characterised in that also include medicine in the powder spray
Acceptable auxiliary material on.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510813416.XA CN106749008A (en) | 2015-11-23 | 2015-11-23 | A kind of method of micronization of maleic acid QAB-149 and its application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510813416.XA CN106749008A (en) | 2015-11-23 | 2015-11-23 | A kind of method of micronization of maleic acid QAB-149 and its application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106749008A true CN106749008A (en) | 2017-05-31 |
Family
ID=58886722
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510813416.XA Pending CN106749008A (en) | 2015-11-23 | 2015-11-23 | A kind of method of micronization of maleic acid QAB-149 and its application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106749008A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101312729A (en) * | 2005-11-21 | 2008-11-26 | 诺瓦提斯公司 | Treatment of asthma and copd using triple-combination therapy |
| CN101896165A (en) * | 2007-12-13 | 2010-11-24 | 诺瓦提斯公司 | Organic compounds |
| CN104208686A (en) * | 2013-05-29 | 2014-12-17 | 天津金耀集团有限公司 | Pharmaceutical composition containing individually-packaged fluticasone and epinephrine beta2-acceptor stimulant placed in inhalation device for synchronous application |
-
2015
- 2015-11-23 CN CN201510813416.XA patent/CN106749008A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101312729A (en) * | 2005-11-21 | 2008-11-26 | 诺瓦提斯公司 | Treatment of asthma and copd using triple-combination therapy |
| CN101896165A (en) * | 2007-12-13 | 2010-11-24 | 诺瓦提斯公司 | Organic compounds |
| CN104208686A (en) * | 2013-05-29 | 2014-12-17 | 天津金耀集团有限公司 | Pharmaceutical composition containing individually-packaged fluticasone and epinephrine beta2-acceptor stimulant placed in inhalation device for synchronous application |
Non-Patent Citations (1)
| Title |
|---|
| 余家会等: "《纳米生物医药》", 31 December 2011 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102846698B (en) | Wall-broken radix tetrastigme oral decoction pieces | |
| US8927523B2 (en) | Compound sea cucumber preparation and manufacturing method thereof | |
| CN112229148A (en) | Vacuum freeze-drying method for pseudo-ginseng and application thereof | |
| CN105079046B (en) | A kind of antitumor soft capsule of full ganoderma lucidum and preparation method thereof | |
| CN102512466B (en) | Panax notoginseng saponins freeze-dried powder injection and preparation method thereof | |
| CN102793733A (en) | Ginseng royal jelly chewable tablets and preparation method thereof | |
| CN104887721A (en) | Ultramicro decoction pieces made of Ganoderma lucidum pure powders, method for preparing ultramicro decoction pieces and application of ultramicro decoction pieces | |
| CN102028730A (en) | Sea cucumber compound preparation, preparation method and usage formulation thereof | |
| CN107647414A (en) | A kind of instant bird's nest collagen Gly-His-Lys | |
| CN103608024B (en) | Control the pharmaceutical composition of blood glucose, blood fat and body weight | |
| CN106942743A (en) | The preparation method of the ecological oral freeze-dried powder of ginseng | |
| CN103961665B (en) | A kind of preparation method of Xiao Chai Hu granules | |
| CN106723075A (en) | A kind of double ginseng sea-buckthorn G-protein saline cistanche zinc selenium preparations and preparation method thereof | |
| CN106749008A (en) | A kind of method of micronization of maleic acid QAB-149 and its application | |
| CN106511414B (en) | Pharmaceutical composition for treating tumors, preparation method and application thereof | |
| CN108371676B (en) | Preparation method of Ligustrum japonicum Thunb super-fine powder for gout | |
| CN106794156A (en) | Micronized insulin, micronized insulin analog and preparation method thereof | |
| CN105012278B (en) | A kind of dry powder inhalation powder spray carrier sucrose and preparation method thereof | |
| CN106727349A (en) | A kind of preparation method for concentrating cornu bubali particle | |
| CN106387904A (en) | Composition, preparation method of composition, preparation and use | |
| CN112168932A (en) | Traditional Chinese medicine composition and extract for preventing new coronary pneumonia, and preparation method and application thereof | |
| CN106880737A (en) | A kind of preparation method of taipei fritillary bulb ultra micro freeze-dried powder | |
| CN107137567A (en) | Cherry freeze-dried powder freezes compound powder and the application in anti-gout drugs are prepared with smilax | |
| CN107496866A (en) | Chinese medicine composition of the treatment childhood asthma containing volatile oil and its preparation method and application | |
| CN113599359B (en) | American ginseng oral disintegrating tablet and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Address after: 102433 No. 8 Doudian Jingbao Road, Fangshan District, Beijing Applicant after: Beijing Yuanda Jiuhe Pharmaceutical Co., Ltd. Address before: 102433 No. 8 Doudian Jingbao Road, Fangshan District, Beijing Applicant before: Jiuhe Pharmaceutical Co., Ltd., Beijing |
|
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170531 |